The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.
The profound influence of Human papillomavirus (HPV) on the epidemiological pattern and clinical course of head and neck cancer (HNSCC) has led to a change in the traditional understanding of this disease entity. Separate therapeutic strategies based on tumour HPV status are under consideration and in this light provision of knowledge concerning the influence of tumour HPV on the radiation response in HNSCC appears highly relevant. This review provides a summary of the current understanding of the role of HPV in head and neck cancer with specific focus on the viral impact on radiotherapy outcome of HNSCC.
Lassen
Pernille
P
Department of Experimental Clinical Oncology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. pernille@oncology.dk
D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy* / Q000821:virology*; D015687:Cell Hypoxia; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006258:Head and Neck Neoplasms / Q000532:radiotherapy* / Q000821:virology*; D006801:Humans; D027383:Papillomaviridae / Q000302:isolation & purification*; D016896:Treatment Outcome
D066246:ErbB Receptors